[ORGANIZATION]
Kv7 Discovery Platform
Featured in 1 tracked story · first seen
Situations
SK Biopharm Opakalim licensing and clinical development
3 clusters · 9 sources · last updated
Latest: Biohaven faces investigation after FDA clinical hold on epilepsy drug
SK Biopharm entered an exclusive worldwide licensing agreement with Biohaven Bioscience Ireland for the epilepsy drug candidate Opakalim (BHV-7000) and its Kv7 Discovery Platform. The deal, valued at up to $795 million,